#NWBO, Re-reading 2018 DCVax-L interim results and actually took the time to look at the authors and where they are all from.
Liau - UCLA
Ashkan - King College
Tran - University of Floria
Campian - Washington University
Trusheim - Abbott NW Hospital
Cobbs - Swedish Medical Center
Heth - University of Michigan
Salacz - University of Kansas Cancer Center
D’Andre - Sutter Institute
Iwamoto - Columbia University
Dropcho - Indiana University Simon Cancer Center
Moshel - Overlook Medical Center
Walter - University of Rochester
Pillainayagam - Rush University Medical Center
Aiken - Rutgers Cancer Institute
Chaudhary - University of Cincinnati Medical Center
Goldlust - Hackensack University Medical Center
Bota - UC Irvine
Duic - Winthrop University
Grewal - NYU Winthrop
Elinzano - Rhode Island Hospital
Toms - Rhode Island Hospital
Lillehei - University of Colorado
Mikkelsen - Henry Ford Health System
Walbert - Henry Ford Health System
Abram - St Thomas Research Institute
Brenner - University of Texas Health Science Center
Brem - University of Pennsylvania
Ewend - University of Carolina
Khagi - University of Carolina
Portnow - City of Hope National Medical Center
Kim - Thomas Jefferson University
Loudon - St Joseph Hospital
Thompson - Vanderbilt University
Avigan - Beth Israel Deaconess Medical Center
Fink - Baylor University Medical Center
Geoffroy - Illinois Cancercare
Lindhorst - Medical University of South Carolina
Lutzky - Mount Sinai Comprehensive Cancer Center
Sloan - University Hospital Case Medical Center
Schackert - University Hospital Carl-Gustav-Carus of Technical University
Krex - University Hospital Carl-Gustav-Carus of Technical University
Meisel - BG - Klinikum Bergmannstrost
Wu - Tufts University
Davis - Stony Brook University
Duma - Hoag Cancer Center
Etame - H. Lee Moffit Cancer Center
Mathieu - CHUS - Hospital Fleurimont
Kesari - UCSD Health System
PIccioni - UCSD Health System
Westphal - Neurochirurgische Klinik University
Baskin - Houston Methodist
New - House Methodist
Lacroix - Geisinger Health System
May - Klinikum Chemnitz
Pluard - St. Luke’s Cancer Institute
Tse - Kaiser Permanente N. California
Green - Kaiser Permanente S. California
Villano - University of Kentucky
Pearlmen - Colorado Neurological Institute
Petrecca - Montreal Neurological Institute
Schulder - Northwell Hofstra SOM
Taylor - University of Washington
Maida - NWBO
Prins - UCLA
Cloughesy - UCLA
Mulloholland - University of College Hospital
Bosch - NWBO
As someone who had 8 years in residency and fellowship training, albeit in a different field, I do know that this is a crazy ridiculous amount of prestigious institutions involved. Physicians in all fields usually look to their peers before they start new treatment regiments.
IMHO, if DCVax-L gets approved by FDA, it would not take much for the product to gain traction given the big academic centers that have already been involved, efficacy and safety profile of DCVax-L.
Also goes to show how ridiculous it is when people call NWBO a fraud.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#NWBO As a physician, there is several reasons why the idea of DCVax-L is exciting. #1. Patient compliance for medication in general is about 50-60%. The higher the side effect profile or burden of treatment, the lower the the compliance rate. DCVax-L immense advantage here.
You know who else hates side effects? Physicians. So when a treatment is given as an intradermal injection (high and known compliance) with such a low side effect profile, its something I am very excited about.
#2. After regulatory approval, you have to ask yourself, will neuro surgeons, neuro oncologist, oncologists be prescribing DCVax-L to their patients? Community physicians typically follow the lead of major academic institutions and thought leaders in their field. See prior post